Article
FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
Leukemia research - 1 Oct 2010
Goemans Bianca F, Zwaan Christian M, Cloos Jacqueline, de Lange Desiree, Loonen Anne H, Reinhardt Dirk, Hählen Karel, Gibson Brenda E S, Creutzig Ursula, Kaspers Gertjan J L
Abstract excerpt
New treatment strategies to improve the outcome of pediatric acute myeloid leukemia (AML) are required as 40% of children diagnosed with AML do not survive. Around 30% of pediatric AML patients harbour a mutation in the tyrosine kinases FLT3 (+/-20%) or KIT (+/-10%). In this study we investigated whether pediatric AML samples (N=61) were sensitive to the tyrosine kinase inhibitor SU11657 (similar to the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.